Kevin Kaplowitz1, Samantha Wang, Richard Bilonick, Julius T Oatts, Tomas Grippo, Nils A Loewen. 1. *Department of Ophthalmology, Stony Brook Medical Center, Stony Brook, NY †Department of Ophthalmology and Visual Sciences, Yale University School of Medicine, New Haven, CT ‡Department of Ophthalmology, University of Pittsburgh Medical Center, Pittsburgh, PA §Department of Ophthalmology, University of California, San Francisco, San Francisco, CA.
Abstract
PURPOSE: To evaluate the clinical effects of laser trabeculoplasty using a novel 790 nm wavelength titanium-sapphire laser (TLT) compared with a 532 nm Q-switched Nd:YAG laser used in standard selective laser trabeculoplasty (SLT). METHODS: Single institution prospective clinical trial of open-angle glaucoma patients randomized to TLT or SLTat the Yale Eye Center from 2011 to 2012. Patients with previous glaucoma surgery or trabeculoplasty were excluded. Trabeculoplasty was performed by a single surgeon unmasked to treatment group. All patients received 360 degrees of treatment. The main outcome measure was intraocular pressure (IOP) at 2 years. RESULTS:Thirty-seven patients were enrolled. The mean baseline IOPs were 19.7 in TLT (n=18) and 20.4 mm Hg in SLT (n=19, P=0.69).At 2 years, the mean IOP was 12.9 mm Hg (35% decrease, P<0.001) in the TLT group and 15.4 mm Hg (25% decrease, P=0.006) in the SLT group. The 2 groups did not differ in glaucoma medication use. Success, defined as IOP<21 mm Hg with >20% reduction from baseline without the need for secondary glaucoma procedures, occurred in 44% of TLT patients and 61% of SLT patients at 1 year and in 22% of TLT patients and 46% of SLT patients at 2 years (P=0.11). No patients experienced significant pain, anterior chamber reaction, corneal edema, or loss of vision. CONCLUSIONS:TLT may be a safe and effective alternative to SLT to lower IOP in patients with open-angle glaucoma.
RCT Entities:
PURPOSE: To evaluate the clinical effects of laser trabeculoplasty using a novel 790 nm wavelength titanium-sapphire laser (TLT) compared with a 532 nm Q-switched Nd:YAG laser used in standard selective laser trabeculoplasty (SLT). METHODS: Single institution prospective clinical trial of open-angle glaucomapatients randomized to TLT or SLT at the Yale Eye Center from 2011 to 2012. Patients with previous glaucoma surgery or trabeculoplasty were excluded. Trabeculoplasty was performed by a single surgeon unmasked to treatment group. All patients received 360 degrees of treatment. The main outcome measure was intraocular pressure (IOP) at 2 years. RESULTS: Thirty-seven patients were enrolled. The mean baseline IOPs were 19.7 in TLT (n=18) and 20.4 mm Hg in SLT (n=19, P=0.69).At 2 years, the mean IOP was 12.9 mm Hg (35% decrease, P<0.001) in the TLT group and 15.4 mm Hg (25% decrease, P=0.006) in the SLT group. The 2 groups did not differ in glaucoma medication use. Success, defined as IOP<21 mm Hg with >20% reduction from baseline without the need for secondary glaucoma procedures, occurred in 44% of TLT patients and 61% of SLT patients at 1 year and in 22% of TLT patients and 46% of SLT patients at 2 years (P=0.11). No patients experienced significant pain, anterior chamber reaction, corneal edema, or loss of vision. CONCLUSIONS: TLT may be a safe and effective alternative to SLT to lower IOP in patients with open-angle glaucoma.
Authors: Gustavo Espinoza; Leonardo Castellanos; Ignacio Rodriguez-Una; Paul Anthony Camacho; Juan Camilo Parra Journal: Int J Ophthalmol Date: 2018-04-18 Impact factor: 1.779
Authors: Christiane R Rolim-de-Moura; Augusto Paranhos; Mohamed Loutfi; David Burton; Richard Wormald; Jennifer R Evans Journal: Cochrane Database Syst Rev Date: 2022-08-09